Selected Publications

Ramos Da Silva J, Bitencourt RK, Formoso PG, Silva SN, Muramtsu H, de OliveiraSM, Porchia M, Ramos Moreno AC, MM Aps LR, Venceslau-Carvalho AA, Tombacz I, Luzetti Fotoran W, Kariko K, Lin PJC, Tam YK, de Oliveira Diniz M, Pardi N, de Souza Ferreira LC: Single dose treatment with self-amplifying or non-replicating mRNA-LNP vaccines controls HPV-associated tumors in mice. Sci Tran Med 15(686): 3464, Mar 2023.

Amanat F, Clark J, Carreno JM, Strohmeier S, Yellin T, Meade PS, Bhavsar D, Muramatsu H, Sun W, Coughlan L, Pardi N, Krammer F: Immunity to Seasonal Coronavirus Spike Proteins Does Not Protect from SARS-CoV-2 Challenge in a Mouse Model but Has No Detrimental Effect on Protection Mediated by COVID-19 mRNA Vaccination. J Virol. online, Feb 2023.

Cesaro A, Lin S, Pardi N, de la Fuente-Nunez C: Advanced delivery systems for peptide antibiotics. Adv Drug Deliv Rev Feb 2023.

Melamed JR, Yerneni SS, Arral ML, LoPresti ST, Chaudhary N, Sehrawat A, Muramatsu H, Alameh MG, Pardi N, Weissman D, Gittes GK, Whitehead KA: Ionizable lipid nanoparticles deliver mRNA to pancreatic B cells via macrophage-mediated gene transfer. Sci Adv 9(4): 1444, Jan 2023.

Schiepers A, van'tWout MFL, Greaney AJ, Zang T, Murammatsu H, Lin PJC, Tam YK, mesin L, Starr TN, Bieniasz PD, Pardi N, Bloom JD, Victora GD: Molecular fate-mapping of serum antibody responses to repeat immunization. Nature Jan 2023.

Gouma S, Furey C, Santos JJS, Parkhouse K, Weirick M, Muramatsu H, Pardi N, Fan SHY, Weissman D, Hensley SE: Nucleoside-Modified mRNA-Based Influenza Vaccines Circumvent Problems Associated with H3N2 Vaccine Strain Egg Adaptation. J. Virol. 91(1): e0172322, Jan 2023.

Gal L, Bellak T, Marton A, Fekecs Z, Weissman D, Torok D, Biju R, Vizler C, Kristof R, Beattie MB, Lin PJC, Pardi N, Nogradi A, Pajer K: Restoration of motor function through delayed instrapinal delivery of human IL-10-Encoding nucleoside-modified mRNA after spinal cord injury. Research 2023.

Verbeke R, Lore K, Hogan MJ, Pardi N.* * corresponding author : Innate immune mechanisms of mRNA vaccines Immunity Nov 2022.

McMahon M, O'Dell G, Tan J, Sárközy A, Vadovics M, Carreño JM, Puente-Massaguer E, Muramatsu H, Bajusz C, Rijnink W, Beattie M, Tam YK, Kirkpatrick Roubidoux E, Francisco I, Strohmeier S, Kanekiyo M, Graham BS, Krammer F, Pardi N.* * corresponding author : Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses. Proc Natl Acad Sci U S A Nov 2022.

Carreño JM, Singh G, Tcheou J, Srivastava K, Gleason C, Muramatsu H, Desai P, Aberg JA, Miller RL, Study Group P, Pardi N, Simon V, Krammer F.: mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations. Vaccine Oct 2022.